IP Library › Granted Patent US 11,925,677
Granted Patent B2
US 11,925,677 · App. 17/862,282 · Granted Mar 12, 2024

Treatment of diabetes and chronic pancreatitis using botulinum toxin

Inventor: Roland M. Williams (Beaumont, TX)
Assignee: Penland Foundation
A61K38/4893A61K9/0019A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,925,677
App. No.
17/862,282
Granted
Mar 12, 2024
Kind
B2
Abstract

A method for treating chronic pancreatitis and diabetes type II in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof.

Claims (20)

1. A method for treating chronic pancreatitis and/or diabetes type II using botulinum toxin, in a patient in need thereof, comprising administering botulinum toxin to the patient, thereby treating chronic pancreatitis and/or diabetes type II, wherein the patient is administered by subcutaneous or intradermal injection, 1-4 units to and/or around the vicinity of a trigeminal nerve, 1-4 units to and/or around the vicinity of a cervical nerve, lateral to the patient's spine, 1-4 units to and/or around the vicinity of a thoracic nerve, lateral to the spine, 1-4 units to and/or around the vicinity of a lumbar nerve, lateral to the spine, and/or 1-4 units to and/or around the vicinity of a sacral nerve, lateral to the spine.

2. The method of claim 1 , wherein the trigeminal nerve comprises an ophthalmic nerve, maxillary nerve, mandibular nerve, supraorbital nerve, supratrochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve, a greater occipital nerve, or a combination thereof.

3. The method of claim 1 , wherein the cervical nerve comprises a c-1 nerve, c-2 nerve, c-3 nerve, c-4 nerve, c-5 nerve, c-6 nerve, c-7 nerve, c-8 nerve, or a combination thereof.

4. The method of claim 1 , wherein the thoracic nerve comprises a t-1 nerve, t-2 nerve, t-3 nerve, t-4 nerve, t-5 nerve, t-6 nerve, t-7 nerve, t-8 nerve, t-9 nerve, t-10 nerve, t-11 nerve, t-12 nerve, or a combination thereof.

5. The method of claim 1 , wherein the lumbar nerve comprises a 1-1 nerve, 1-2 nerve, 1-3 nerve, 1-4 nerve, 1-5 nerve, or a combination thereof.

6. The method of claim 1 , wherein the sacral nerve comprises an s-1 nerve, s-2 nerve, s-3 nerve, s-4 nerve, s-5 nerve, or a combination thereof.

7. The method of claim 1 , wherein the botulinum toxin comprises botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F and botulinum toxin type G, a fragment thereof, a hybrid thereof, a chimera thereof, or a combination thereof.

8. The method of claim 1 , wherein each of the subcutaneous or intradermal injection is bilateral.

9. The method of claim 1 , wherein a total dosage of the botulinum toxin for an adult who weighs about 150 lbs. is between about 1 unit and about 150 units.

10. The method of claim 1 , wherein a total dosage of the botulinum toxin for an adult or a child is adjusted for age, weight, or a combination thereof.

11. The method of claim 10 , wherein the total dosage contains therapeutically effective amount of botulinum toxin.

12. The method of claim 11 , wherein the therapeutically effective amount is 1-50 units.

13. The method of claim 12 , wherein the therapeutically effective amount is 1-30 units.

14. The method of claim 13 , wherein the therapeutically effective amount is 1-4 units.

15. The method of claim 14 , wherein the therapeutically effective amount is 2-4 units.

16. The method of claim 1 , wherein each of the injections is 2-4 units.

17. The method of claim 1 further comprises monitoring a physical symptom, a blood glucose level and/or a neuroexcitatory substance level from the patient.

18. The method of claim 17 , wherein the neuroexcitatory substance comprises substance P, calcitonin gene-related peptide (CGRP) or glutamate.

19. The method of claim 17 further administering additional botulinum toxin to the patient if the physical symptom, the blood glucose level and/or the neuroexcitatory substance level fails to normalize.

20. The method of claim 1 , wherein botulinum toxin is the only pharmaceutically active ingredient for the treatment.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2022
From: WILLIAMS, ROLAND M.
To: PENLAND FOUNDATION
Reel/Frame 060545/0950 →
Continuity (2)
Provisional Application 63220960 · Jul 12, 2021
Related Publication 20230011705A1 · Jan 12, 2023